NCT04277338View on ClinicalTrials.gov

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

October 4, 2021

Conditions
Primary Breast Cancer
Interventions
DRUG

SPECT

One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.

Trial Locations (1)

Unknown

TomskNRMC, Tomsk

All Listed Sponsors
collaborator

Institute of Bioorganic Chemistry, Russian Academy of Sciences

UNKNOWN

collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT04277338 - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 | Biotech Hunter | Biotech Hunter